Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Top 3 drug approvals in oncology: September 2021

Written by Jade Parker, Senior Editor

drug approval september

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Highlights include the approval of Exkivity®, as well as its companion diagnostic device by the US FDA, and the approval of Erleada® by NICE in the UK. Erleada® (apalutamide) Approved:  8 September 2021 Company: Janssen (EMEA) Indication: Prostate cancer At the start of September NICE published final draft guidance recommending apalutamide plus androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer and hormone-sensitive metastatic prostate cancer if docetaxel is not...

To view this content, please register now for access

It's completely free